Table 3 Poisson regression model for the incidence of all-cause mortality, AIDS-related mortality, and non-AIDS-related mortality among people living with HIV on ART for each third drug comparison

From: Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China

 

All-cause mortality

AIDS-related mortality

Non-AIDS-related mortality

aIRR (95% CI)

p value

aIRR (95% CI)

p value

aIRR (95% CI)

p value

EFV vs NVP

0.64(0.53–0.79)

<0.001

0.49(0.40–0.62)

<0.001

1.35(0.86–2.11)

0.198

DTG vs NVP

0.27(0.11–0.67)

0.004

0.17(0.08–0.40)

<0.001

0.75(0.18–3.07)

0.687

LPV vs NVP

0.49(0.33–0.75)

0.001

0.20(0.12–0.33)

<0.001

1.68(0.83–3.43)

0.151

Others vs NVP

2.22(0.51–9.74)

0.291

0.29(0.08–1.07)

0.062

7.74(1.03–58.17)

0.047

DTG vs EFV

0.68(0.28–1.62)

0.385

0.64(0.24–1.69)

0.366

0.73(0.17–3.08)

0.673

LPV vs EFV

0.88(0.62–1.27)

0.499

0.46(0.29–0.74)

0.001

1.48(0.90–2.42)

0.119

Others vs EFV

2.39(0.88–6.48)

0.088

0.71(0.11–4.80)

0.726

5.78(1.54–21.71)

0.009

LPV vs DTG

1.44(0.52–3.98)

0.484

1.02(0.36–2.94)

0.967

1.95(0.39–9.71)

0.415

Others vs DTG

3.57(0.72–17.65)

0.119

2.28(0.62–8.48)

0.217

6.62(0.39–113.87)

0.193

Others vs LPV

2.26(0.74–6.90)

0.152

0.93(0.08–10.67)

0.951

3.06(0.95–9.90)

0.062

  1. ART, antiretroviral therapy. NVP, nevirapine. EFV, efavirenz. DTG, dolutegravir. LPV, lopinavir. Others= darunavir, raltegravie, elvitegravir and rilpivirine. aIRR, adjusted incidence rate ratio. Poisson regression model with a time offset and robust variances was adjusted for main variables, including baseline age, sex, route of HIV acquisition, region, time to ART initiation, year of ART initiation, CD4 + T-cell counts, and NRTI backbone. NRTI, nucleotide reverse transcriptase inhibitor.
Back to article page